AMEDISYS INC (AMED) Fundamental Analysis & Valuation

NASDAQ:AMED • US0234361089

Current stock price

100.99 USD
+0.01 (+0.01%)
At close:
100.99 USD
0 (0%)
After Hours:

This AMED fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. AMED Profitability Analysis

1.1 Basic Checks

  • AMED had positive earnings in the past year.
  • AMED had a positive operating cash flow in the past year.
  • AMED had positive earnings in 4 of the past 5 years.
  • AMED had a positive operating cash flow in each of the past 5 years.
AMED Yearly Net Income VS EBIT VS OCF VS FCFAMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

1.2 Ratios

  • AMED has a better Return On Assets (3.87%) than 72.12% of its industry peers.
  • AMED has a better Return On Equity (6.95%) than 66.35% of its industry peers.
  • AMED has a Return On Invested Capital of 10.34%. This is amongst the best in the industry. AMED outperforms 81.73% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for AMED is in line with the industry average of 8.40%.
  • The last Return On Invested Capital (10.34%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.87%
ROE 6.95%
ROIC 10.34%
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
AMED Yearly ROA, ROE, ROICAMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

  • The Profit Margin of AMED (3.56%) is better than 68.27% of its industry peers.
  • In the last couple of years the Profit Margin of AMED has declined.
  • Looking at the Operating Margin, with a value of 9.41%, AMED is in the better half of the industry, outperforming 78.85% of the companies in the same industry.
  • AMED's Operating Margin has been stable in the last couple of years.
  • Looking at the Gross Margin, with a value of 43.19%, AMED is in the better half of the industry, outperforming 71.15% of the companies in the same industry.
  • AMED's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.41%
PM (TTM) 3.56%
GM 43.19%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
AMED Yearly Profit, Operating, Gross MarginsAMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AMED Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMED is creating some value.
  • AMED has more shares outstanding than it did 1 year ago.
  • AMED has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AMED has an improved debt to assets ratio.
AMED Yearly Shares OutstandingAMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
AMED Yearly Total Debt VS Total AssetsAMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 4.10 indicates that AMED is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.10, AMED is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • AMED has a debt to FCF ratio of 1.55. This is a very positive value and a sign of high solvency as it would only need 1.55 years to pay back of all of its debts.
  • The Debt to FCF ratio of AMED (1.55) is better than 85.58% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that AMED is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.26, AMED is in the better half of the industry, outperforming 65.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.55
Altman-Z 4.1
ROIC/WACC1.2
WACC8.61%
AMED Yearly LT Debt VS Equity VS FCFAMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 1.36 indicates that AMED should not have too much problems paying its short term obligations.
  • The Current ratio of AMED (1.36) is comparable to the rest of the industry.
  • AMED has a Quick Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
  • AMED's Quick ratio of 1.36 is in line compared to the rest of the industry. AMED outperforms 50.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.36
AMED Yearly Current Assets VS Current LiabilitesAMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMED Growth Analysis

3.1 Past

  • AMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.24%, which is quite good.
  • The Earnings Per Share has been decreasing by -0.46% on average over the past years.
  • Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 4.93% in the last year.
  • AMED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.73% yearly.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%

3.2 Future

  • Based on estimates for the next years, AMED will show a small growth in Earnings Per Share. The EPS will grow by 6.47% on average per year.
  • AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.95% yearly.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AMED Yearly Revenue VS EstimatesAMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
AMED Yearly EPS VS EstimatesAMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. AMED Valuation Analysis

4.1 Price/Earnings Ratio

  • AMED is valuated rather expensively with a Price/Earnings ratio of 21.26.
  • Compared to the rest of the industry, the Price/Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 67.31% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.54, AMED is valued at the same level.
  • AMED is valuated rather expensively with a Price/Forward Earnings ratio of 19.15.
  • Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than the industry average as 62.50% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of AMED to the average of the S&P500 Index (21.68), we can say AMED is valued inline with the index average.
Industry RankSector Rank
PE 21.26
Fwd PE 19.15
AMED Price Earnings VS Forward Price EarningsAMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 65.38% of the companies in the same industry are more expensive than AMED, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than 78.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.18
EV/EBITDA 11.63
AMED Per share dataAMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMED Dividend Analysis

5.1 Amount

  • AMED does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AMED Fundamentals: All Metrics, Ratios and Statistics

AMEDISYS INC

NASDAQ:AMED (8/14/2025, 8:02:42 PM)

After market: 100.99 0 (0%)

100.99

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry Strength49.07
Industry Growth88.82
Earnings (Last)07-29
Earnings (Next)11-04
Inst Owners92.54%
Inst Owner Change0%
Ins Owners1.88%
Ins Owner Change0%
Market Cap3.32B
Revenue(TTM)2.40B
Net Income(TTM)85.63M
Analysts54.12
Price Target102.87 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.78%
Min EPS beat(2)12.12%
Max EPS beat(2)13.43%
EPS beat(4)2
Avg EPS beat(4)-0.15%
Min EPS beat(4)-15.99%
Max EPS beat(4)13.43%
EPS beat(8)3
Avg EPS beat(8)-1.75%
EPS beat(12)6
Avg EPS beat(12)2.15%
EPS beat(16)9
Avg EPS beat(16)3.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-1.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.17%
Revenue beat(16)2
Avg Revenue beat(16)-2.65%
PT rev (1m)0%
PT rev (3m)0.02%
EPS NQ rev (1m)7.75%
EPS NQ rev (3m)3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0.63%
Revenue NQ rev (3m)-0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.48%
Valuation
Industry RankSector Rank
PE 21.26
Fwd PE 19.15
P/S 1.38
P/FCF 14.18
P/OCF 13.87
P/B 2.69
P/tB N/A
EV/EBITDA 11.63
EPS(TTM)4.75
EY4.7%
EPS(NY)5.27
Fwd EY5.22%
FCF(TTM)7.12
FCFY7.05%
OCF(TTM)7.28
OCFY7.21%
SpS73.04
BVpS37.47
TBVpS-1.84
PEG (NY)1.61
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 3.87%
ROE 6.95%
ROCE 13.09%
ROIC 10.34%
ROICexc 12.85%
ROICexgc 184.87%
OM 9.41%
PM (TTM) 3.56%
GM 43.19%
FCFM 9.75%
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexgc growth 3Y57.65%
ROICexgc growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score6
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.55
Debt/EBITDA 1.13
Cap/Depr 8.5%
Cap/Sales 0.22%
Interest Coverage 8.42
Cash Conversion 83.2%
Profit Quality 273.49%
Current Ratio 1.36
Quick Ratio 1.36
Altman-Z 4.1
F-Score6
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y8.08%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year19.91%
EBIT Next 3Y9.46%
EBIT Next 5YN/A
FCF growth 1Y132.55%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y110.02%
OCF growth 3Y5.48%
OCF growth 5Y1.88%

AMEDISYS INC / AMED Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AMEDISYS INC?

ChartMill assigns a fundamental rating of 5 / 10 to AMED.


Can you provide the valuation status for AMEDISYS INC?

ChartMill assigns a valuation rating of 5 / 10 to AMEDISYS INC (AMED). This can be considered as Fairly Valued.


What is the profitability of AMED stock?

AMEDISYS INC (AMED) has a profitability rating of 7 / 10.


What are the PE and PB ratios of AMEDISYS INC (AMED) stock?

The Price/Earnings (PE) ratio for AMEDISYS INC (AMED) is 21.26 and the Price/Book (PB) ratio is 2.69.